Abstract | Increasing evidence points to a central role for immune dysregulation in autism spectrum disorder (ASD). Several ASD risk genes encode components of the immune system and many maternal immune system-related risk factors -including autoimmunity, infection and fetal reactive antibodies -are associated with ASD. In addition, there is evidence of ongoing immune dysregulation in individuals with ASD and in animal models of this disorder. Recently, several molecular signalling pathways -including pathways downstream of cytokines, the receptor MET, major histocompatibility complex class I molecules, microglia and complement factors -have been identified that link immune activation to ASD phenotypes. Together, these findings indicate that the immune system is a point of convergence for multiple ASD-related genetic and environmental risk factors.
1
. The estimated prevalence of ASD has recently skyrocketed: in 1992, it was estimated that 1 in 500 children in the United States had ASD, but by 2007 this figure had been adjusted to 1 in 110, and current estimates have reached the alarming level of 1 in 68 children (and 1 in 42 boys) in the United States 2 . Although the wider diagnostic criteria for, and enhanced public awareness of, ASD have surely contributed to this increase, these factors cannot account for all -and in some estimates most -of this rise in prevalence 3 . This gap implies that one or more factors in our environment have increased the likelihood of children developing ASD. Consistent with this idea, recent reports have suggested that the environment may have a much larger role in causing ASD than had been initially proposed 4, 5 . Although there are many diverse environmental factors that contribute to ASD 6 , most of these converge on alterations in immune responses during prenatal or early postnatal development (FIG. 1) . The immune system is designed to reflect environmental changes and to predict future changes as a defensive strategy. The genetic composition and initial programming of the immune system in utero and shortly after birth 7, 8 determine how much environmental insult the immune system can buffer during the lifetime of each individual. This buffering is important not only for general health but also for neural processing owing to the pervasive and dynamic crosstalk that occurs between the immune and nervous systems. Indeed, immune status can have profound effects on brain development and cognition (BOX 1) , and alterations in immune signalling can, in different contexts, induce beneficial, homeostatic or harmful effects.
Similar to ASD, childhood disorders of the immune system such as asthma, life-threatening food allergies and autoimmune disorders have reached epidemic levels over the past two decades 9, 10 . As this time frame is too short for genetic changes at a population level to have had an appreciable impact on the prevalence of these conditions, these increases must have an environmental catalyst. It is hypothesized that the rise in childhood immune disorders reflects the exposure to an increasing number of environmental stressors during critical periods of development that results in disease expression in individuals with a vulnerable genetic background 11 . This multiple-hit model for immune disorders is also hypothesized in the aetiology of ASD 6, 12 . Although accumulating evidence indicates that immune dysregulation increases the risk, and contributes to the pathophysiology, of ASD, this does not mean that immune responses to vaccines cause ASD. In fact, recent studies have debunked the myth of a link between ASD and early childhood vaccinations 13 . Despite the unequivocal and compelling research behind
Autoimmune disorders
Disorders wherein the immune system attacks normal substances and tissues of the body.
Single-nucleotide polymorphism (SNP) . The most common form of genetic variation due to nucleotide substitutions.
the conclusion that vaccines do not cause ASD, society is increasingly at risk of preventable devastating diseases -including whooping cough, measles and tuberculosis -because of the unsubstantiated fear of vaccinations. For these reasons alone, it is crucial to disseminate and to improve our understanding of immune and environmental contributions to ASD.
In this Review, we provide an overview of the evidence that maternal and postnatal immune dysregulation play a part in the aetiology and pathophysiology of ASD. First, we examine evidence from genetic studies that indicates an association between ASD and mutations in immune genes. Next, we discuss the epidemiological, clinical and animal studies implicating prenatal immune system contributions to ASD, including autoimmunity, fetal reactive antibodies and maternal immune activation (MIA). Then, we review the evidence for chronic immune perturbations in individuals with ASD. Finally, we present the molecular mechanisms that might underlie the link between immune activation and ASD phenotypes, focusing on common molecular pathways that might be targeted by future, novel therapeutic interventions.
Genetic studies
Early estimates of the heritability of ASD of approximately 90% 14, 15 , and even recently revised estimates of 38-54%, strongly suggest that genetic mutations are a major cause of ASD 4, 16 . However, so far, no single gene has been identified that substantially increases the risk of developing ASD 17 . Instead, ASD seems to be associated with a large number of genetic mutations, including possibly hundreds of rare causal variants and more than 100 common variants of small effect 18, 19 . Insight into the genetic pathways that are altered in ASD has come from studies of syndromic disorders with a high incidence of ASD, including fragile X syndrome, Rett syndrome, tuberous sclerosis, neurofibromatosis type 1 and PTEN (phosphatase and tensin homologue) macrocephaly. These syndromes are caused by mutations in single genes (fragile X mental retardation 1 (FMR1), methylCpG-binding protein 2 (MECP2), tuberous sclerosis 1 (TSC1) or TSC2, neurofibromin 1 (NF1) and PTEN, respectively) and account for 5-7% of ASD cases [20] [21] [22] . Recent reports have also highlighted the strong contribution of copy number variants to ASD, accounting for 7-20% of cases of this disorder [23] [24] [25] . Importantly, several ASD-associated genes encode components of the immune system (TABLE 1). One of the immune genes most associated with ASD is MET, which encodes a receptor that binds hepatocyte growth factor (HGF) 26 . A MET variant that includes a common G-to-C single-nucleotide polymorphism (SNP) in its promoter (the rs1858830 'C' allele) is associated with decreased MET signalling in the temporal lobe and ASD [27] [28] [29] . This MET variant leads to the disrupted expression of multiple downstream targets of the MET signalling cascade 28 .
Post-mortem transcriptome analysis of individuals with ASD also shows reduced MET expression in the temporal lobe, suggesting that reduced MET levels may indeed cause ASD phenotypes 27, 30, 31 . Consistent with this idea, individuals with ASD and the MET 'C' allele exhibit reduced structural and functional connectivity in the temporoparietal lobes compared with both individuals with Figure 1 | ASD risk factors during pregnancy converge on maternal immune system activation. Maternal autoimmunity, infection during pregnancy, maternal age and obesity, gestational diabetes, and maternal MET variant rs1858830 'C' allele are all associated with a higher incidence of autism spectrum disorder (ASD). These risk factors (red boxes) cause maternal immune activation (MIA) (blue boxes), which manifests as changes in the maternal peripheral cytokine milieu, generation of immunoglobulin G (IgG) maternal autoantibodies that are reactive to fetal proteins, and activation of inflammatory pathway genes within the placenta. Based on findings in animal models, MIA is sufficient to induce long-lasting changes in brain development, the gut microbiota, and immune and endocrine systems, all of which can lead to altered cognition and behaviour in the developing fetus (green boxes).
Human leukocyte antigen
(HLA). The gene locus that encodes the human versions of three different classes of major histocompatibility complex proteins.
Complement
A system of plasma proteins that attack extracellular pathogens, assist in pathogen and cellular debris clearance by phagocytes and facilitate synaptic pruning in the brain.
ASD but without the MET variant and control individuals 31 . Moreover, structural MRI in individuals with ASD and the MET 'C' allele shows decreased cortical thickness in several brain regions that are associated with sociocommunicative function 32 . Interestingly, MeCP2, which is implicated in Rett syndrome, regulates MET transcription, and the expression of MET is notably reduced in the temporal lobes of females with Rett syndrome in the absence of the MET 'C' allele 33 , suggesting that reduced MET expression may contribute to the ASD-related pathophysiology in this syndrome.
Many of the ASD-related phenotypes that are associated with decreased MET signalling in the brain may result from deficits in the key functions that MET has in brain development (described below). However, MET could also cause these changes in neural circuitry and function indirectly through its ability to negatively regulate immune responsiveness 34, 35 and gastrointestinal homeostasis 36, 37 . Increased MET signalling ameliorates disease pathogenesis in several models of classic systemic inflammatory diseases, including multiple sclerosis and systemic lupus erythematosis (SLE) [38] [39] [40] [41] [42] . Moreover, during pregnancy, the MET 'C' allele is associated with a decrease in the production of the cytokine interleukin-10 (IL-10) 43 , thus preventing the important gestational increase in IL-10 that is responsible for maternal immune suppression and tolerance to the developing fetus 44 (FIG. 1) . The MET 'C' allele is also enriched in mothers with another immune-related risk factor for ASD -maternal antibodies that are reactive to fetal brain proteins 43 (discussed below). Finally, the MET 'C' allele may interact with environmental factors to increase the risk of ASD. Indeed, the MET 'C' allele and exposure to high levels of air pollution during prenatal development act synergistically to increase the risk of developing this disorder 45 . In addition to variants in MET, variants in the human leukocyte antigen (HLA) locus confer risk of neurodevelopmental disorders 46, 47 . The HLA locus encodes the major histocompatibility complex (MHC) genes in humans, which are involved in diverse immune functions and comprise three classes. Although the limited scale of the genetic studies of MHC in relation to ASD does not allow any definitive associations to be made, variants in all three classes of MHC genes have been reported to enhance ASD risk: namely, the MHC class I (MHCI) HLA-A2 haplotype, the MHCII HLA-DRB1 alleles and the complement C4B-null allele in the MHCIII region 47 . As with many other ASD-related genes, the HLA associations are not specific to ASD; they are also associated with other neurodevelopmental disorders and autoimmune disorders, including rheumatoid arthritis and SLE 48 , which occur at higher rates in the relatives of individuals with ASD 49 . The combination of a specific HLA-DRB1*11 allele with a family history of auto immune disorders increases the odds ratio for the association of this allele with ASD 50 . Similarly, ASD-associated deficiencies in a complement gene -C4 -within the MHCIII region 51, 52 are also among the strongest genetic risk factors for SLE 53 , and individuals with idiopathic ASD exhibit a 34% decrease in plasma levels of C4b 54 . These ASD-linked deficits in complement are thought to lead to the activation of autoimmune responses directly, owing to the production of autoantibodies against excess cellular debris that is typically removed in a complement-dependent manner, and indirectly, through the chronic immune activation that is caused by recurrent and persistent bacterial infections 55 . Finally, mutations in genes that encode several members of the IL-1 cytokine receptor family are also associated with ASD. Two recent exome-sequencing studies of individuals with ASD found synonymous SNPs in the gene encoding the IL-1β decoy receptor IL-1 receptor type 2 (IL-1R2) 56, 57 . The functional consequences of these SNPs have not yet been assessed, but synonymous SNPs can affect protein folding and mRNA splicing, stability and structure 58, 59 . A rare ASD-associated mutation has also been identified in the gene encoding another IL-1 family receptor, IL-1 receptor accessory protein-like 1 (IL-1RAPL1) 60, 61 . This mutation was originally identified in a screen for genes that are related to X-linked intellectual disability 62 . ASD-associated mutations, copy number variants and somatic mosaics have subsequently been discovered in this gene, most of which result in a loss of function of the encoded protein 63 . Together, these findings indicate that mutations in a wide array of immune genes contribute to ASD.
Maternal immune contributions
Autoimmune disorders. Although genetic mutations seem to contribute a sizeable amount of risk of ASD, recent estimates suggest that 50-60% of the risk of ASD is unaccounted for, which implies that environmental
Box 1 | Immune system influences on cognition and behaviour
In the past 10 years, it has become increasingly clear that the immune status of an individual influences cognition and behaviour. In addition to mediating the response to disease, immune cells, especially T cells, have roles in many aspects of brain development and function 249, 250 . This is perhaps best illustrated in mice with severe combined immunodeficiency (SCID) and nude mice, which are deprived of all lymphocytes and T cells, respectively. These animals exhibit impairments in hippocampal neurogenesis and learning and memory, as well as increased repetitive behaviours and anxiety 251, 252 . Remarkably, replenishment of the immune system by adoptive transfer of wild-type splenocytes or by bone marrow reconstitution improves the learning ability of SCID and nude mice in several learning tasks and ameliorates repetitive behaviours 132, 253, 254 , suggesting that the defects are not caused by lifelong immune deficiency but rather by ongoing depletion of immune cells. Interestingly, increased anxiety is not rescued by wild-type reconstitution, suggesting that anxiety has a developmental aetiology and is a lasting behavioural consequence of impaired immunity 252 . CD4
+ T cells mediate pro-cognitive effects 255 indirectly through effects at meningeal spaces rather than through infiltration into the CNS 256 . When mice are exposed to learning tasks, T cells home to the meninges and become activated, acquiring a T helper 2 (T H 2)-like phenotype (regarded as anti-inflammatory) and expressing high levels of interleukin-4 (IL-4), which cause myeloid cells in the meninges to become skewed to an M2 (also anti-inflammatory) phenotype 256 . Preventing this T cell migration to the meninges, or genetic deletion of Il4, results in a pro-inflammatory, M1 skewing of meningeal myeloid cells and deficits in learning and memory 256 . Conversely, reconstituting wild-type mice with T cells from Il4-knockout mice results in learning and memory deficits 132 . Thus, CD4 + T cells, which clearly regulate brain immune status, normal cognition and emotional behaviour, may have important roles in causing and/or contributing to autism spectrum disorder and clearly represent an important potential therapeutic target for this condition. 
Maternal immunoglobulin G (IgG) antibodies
IgG antibodies that pass through the placenta during the third trimester and enter fetal circulation, where they persist at high titre levels for several months after birth. 
Blood-brain barrier

Fetal-brain-reactive antibodies
Maternally derived immunoglobulin G antibodies that can cross the placenta and bind to fetal brain proteins.
factors or gene-environment interactions contribute substantially to the risk of this disorder 4, 16 . In addition to mutations in immune genes, autoimmune disorders, allergies and asthma are strongly associated with the families of children with ASD 49 . Estimates indicate that there is up to a 50% increase in the odds of an ASD diagnosis among children who have a parent who has had an autoimmune disorder 49, 64 . Although maternal immune disorders such as rheumatoid arthritis, SLE and type 1 diabetes account for the largest proportion of this increased risk of ASD in offspring, paternal immune disorders and a general familial history of immune disorders in the absence of maternal immune conditions also seem to contribute, suggesting that there is a heritable component for this autoimmune association 49, 65 . Indeed, autoimmune disorders are over-represented in the population of individuals with ASD 66 . However, such disorders also increase the risk of intellectual disability and several other neurodevelopmental disorders, suggesting that immune disorders generally increase the vulnerability of the developing brain to developmental defects 67 . The strong contribution of maternal immune status to ASD risk could involve genetic factors and environmental influences on the developing fetus. Similar to the situation caused by the MET 'C' allele, mothers with autoimmune disorders fail to develop an anti-inflammatory immune system profile that is typical during pregnancy 68 
(FIG. 1).
Although the relative contributions of these genetic and environmental factors are yet to be determined, animal models show a causal link between the activation of the maternal immune system and altered neurodevelopment (see below).
Fetal-brain-reactive antibodies.
The association of maternal autoimmune disorders with ASD in offspring may be mediated by the passive transfer to the fetus of maternal immunoglobulin G (IgG) antibodies that exhibit reactivity to self-proteins in the mother or child. In typical development, passive immunity protects the fetus and early neonate from infection until the child's adaptive immune system has matured. These fetal maternal IgG antibodies could theoretically enter the fetal brain during early gestation because the blood-brain barrier (BBB) is not mature until the postnatal period 69 . Bolstering this hypothesis, women with rheumatoid arthritis or SLE are more than four times as likely as women without these disorders (10.5% versus 2.6%) to harbour peripheral antibodies with reactivity to neurons from the brains of fetal and adult mice 70 . Moreover, 53% of mothers of a child with ASD who test positive for anti-brain antibodies also have anti-nuclear antibodies -an indicator of latent autoimmunity -compared with 13.4% of mothers of a child with ASD who do not test positive for anti-brain antibodies 70 . Thus, autoimmunity in pregnant women, even at a clinically undetectable level, may be associated with the production of maternal antibodies that can reach the fetal brain and potentially perturb fetal brain development.
A functional role for such maternal auto antibodies has recently been demonstrated by several groups. Injecting NMDA receptor (NMDAR)-specific autoantibodies derived from the blood of patients with SLE into a pregnant mouse alters brain development and impairs cognitive behaviour in the offspring 71 . Antibody clones that recognize the NR2A and NR2B NMDAR subunits seem to be a major cause of these behavioural changes. Interestingly, although 30-60% of individuals with SLE have NMDAR-specific autoantibodies, each antibody clone has unique physiological effects. Some antibodies have potent co-agonist properties, leading to an increased calcium influx through NMDARs and eventually neuronal death 72 , whereas other clones with slightly different epitopes are not pathogenic and still others cross-react with C1q, a component of the complement cascade 73 . Remarkably, the effects of these NMDARspecific antibodies are sex specific in mice: they cause death through apoptosis of NR2A-expressing neurons, which are enriched in the brainstem of female fetuses but not male fetuses 74 . A female-specific vulnerability to these antibodies could result in increased rates of resorption of female fetuses and lead to an increase in the proportion of male offspring, similar to the male skewing seen in ASD. In addition, female fetuses with these antibodies that are carried to term would be expected to show more profound deficits. This prediction may fit with the recurrent observation that a subset of girls with ASD shows more social communication impairments and lower cognitive abilities than boys with matched low IQs 75 . Collectively, these results suggest mechanisms whereby maternal autoimmuntity can impair brain development in offspring in a sex-specific manner.
Fetal-brain-reactive antibodies have also been found in approximately 11% of mothers of children with ASD in the absence of any evidence of autoimmunity. These antibodies recognize fetal brain proteins of 37 kDa, 39 kDa and 73 kDa, and may confer specific pathophysiology (such as abnormal brain enlargement, self-injurious behaviour and greater language deficits) depending on the antibody clone 76 . Several studies suggest that these maternal IgG antibodies are ASD specific, as these antibodies did not detect proteins of these sizes in mothers of unaffected children 76 . However, it is currently unknown whether these ASD-specific maternal IgG antibodies are sufficient to cause ASD. Additional studies are needed to determine the risk of developing ASD in subsequent children born to mothers harbouring ASD-specific antibodies and, therefore, whether these banding patterns could be used as an ASD biomarker.
Seven proteins -lactate dehydrogenase A (LDHA), LDHB, Y-box-binding protein 1 (YBX1), guanine deaminase (cypin), stress-induced phosphoprotein 1 (STIP1), collapsin response mediator protein 1 (CRMP1; also known as DRP1) and CRMP2 (also known as DRP2) -have recently been reported to be targeted by fetalbrain-reactive antibodies. These seven proteins are expressed in the developing brain, where they have roles in growth cone motility, dendritic morphology, cellular stress and metabolism, and/or transcription regulation 77 . Disrupting the function of any of these proteins can alter brain development, thereby contributing to ASD pathogenesis. Indeed, injecting pregnant non-human primates with maternal IgG antibodies from mothers of ASD children induces ASD-like behavioural changes in offspring, including reduced reciprocal interactions and inappropriate approach behaviours 78, 79 . In addition, these offspring have larger brains -including larger frontal lobes -which may be consistent with the aberrant white matter tracts found in a subset of young children with ASD [79] [80] [81] [82] . Similar species-specific aberrant social behaviours in offspring are induced when pregnant mice are injected with human IgG-ASD 83 . Moreover, a single lowdose intraventricular injection of IgG-ASD at mid-gestation in mice causes increases in repetitive behaviours and alterations in social approach behaviour 84 . Thus, the presence of maternally derived brain-directed autoantibodies in early development is associated with a higher incidence of ASD and specific pathophysiology. Research is ongoing to determine whether these fetal antibodies exert their functions by acting directly on their protein targets in the brain and to determine which targets are causal for specific ASD phenotypes.
Maternal infection.
In addition to maternal antibodies, acute immune activation that is caused by maternal infection during specific periods of gestation contributes to ASD risk in offspring 85 . Maternal infection was first associated with ASD following the observation that ASD incidence increased from 0.05% to 8-13% in children of mothers that were exposed to the 1964 rubella pandemic during pregnancy [86] [87] [88] . Numerous single-case studies have also associated ASD with various parasitic, bacterial and viral prenatal infections, including toxoplasmosis, syphilis, varicella, cytomegalovirus, mumps and herpes simplex virus infection 85 . This diversity of infectious agents suggests that general immune activation during gestation, rather than a specific immune disorder or virus, underlies the link with ASD. Consistent with this idea of heightened immune activity and infection, several recent studies have reported increased levels of proinflammatory cytokines in the amniotic fluid of mothers of children with ASD 89, 90 . Definitive evidence that maternal infection during pregnancy is a risk factor for ASD in offspring was obtained through more recent studies of the Danish health registry 91 . Data from more than one million children born between 1980 and 2005 revealed an almost threefold increase in the rate of ASD diagnosis in children born to mothers who were hospitalized for viral infection in the first trimester and in children of women who experienced an episode of fever lasting 1 week or more before gestational week 32 (REFS 91, 92) . These data point to a specific temporal window of immune activation during the first trimester of fetal development, and the association with a specific duration of fever suggests that an immune activation threshold must be surpassed to confer risk of developing ASD. It is important to note that most maternal infections that fall within this timewindow and are above this threshold do not lead to ASD in offspring, suggesting that both the immune status of the mother and the immuno genetic background of the developing child may be critical factors in determining outcome. In support of this hypothesis, a recent study using a mouse model of MIA found that the degree of maternal immune response (as measured by weight loss and tumour necrosis factor (TNF) serum levels) to prenatal immune challenge with polyinosinic-polycytidylic acid (poly(I:C)), a viral mimic, is positively associated with the severity of sensorimotor gating deficits in the offspring 93 . Finally, similar to maternal autoimmune disorders, maternal infection during pregnancy has been associated with other developmental disorders, including schizophrenia and mood disorders 94 . It has been proposed that the specific combination of gestational week, type of immune activation (viral, bacterial or chronic) and the duration or intensity of activation may determine which disorder manifests in offspring 12 . Studies using several animal models of maternal infection during pregnancy support the association of MIA with ASD phenotypes. These models include influenza infection, viral and bacterial mimics (poly(I:C) and lipopolysaccharide, respectively) and specific cytokines, such as IL-2 and IL-6. These studies support the idea that the timing of MIA and the type of antigen that is used for immune challenge can lead to overlapping but distinct phenotypes, including behavioural outcomes and transcriptome signatures in the developing brains of offspring 95 . Poly(I:C) injection at mid-gestation in mice and non-human primates generates offspring that display all (in mice) or some (in non-human primates) of the three core behavioural symptoms of ASD [96] [97] [98] . Both mouse and non-human primate MIA offspring also exhibit deficiencies in sensorimotor gating and increased anxiety; these co-morbidities are also observed in a subset of individuals with ASD. In addition, mouse MIA offspring show localized aberrations in Purkinje cells 99 , similar to the localized deficits in cerebellar Purkinje cells that have been reported in many post-mortem ASD cases 100 . These MIA-induced ASD-like behaviours and neuropathologies in offspring seem to be caused by altered levels of maternal cytokines, including IL-2, IL-6 and IL-10. Both a single injection of IL-6 at mid-gestation or low-dose IL-2 injections daily between gestational days 12 and 16 in mice are sufficient to induce ASD-like behavioural changes and neuropathologies in offspring, including deficits in sensorimotor gating, increased anxiety and stereotypical behaviour, aberrant social interactions, and increased serum levels of pro-inflammatory cytokines 96, 101 . Maternal cytokines also seem to be necessary for the ASD-like phenotypes in offspring because poly(I:C) injections at mid-gestation on an Il6-knockout background, co-administration of an IL-6 functionblocking antibody and poly(I:C), or overexpression of the anti-inflammatory cytokine IL-10 by macrophages prevent the MIA-induced changes in gene expression and behaviour 96, 102 . Despite several considerations in interpreting the findings from animal models of ASD
, these results provide strong support for the involvement of MIA in the development of ASD in offspring.
Chronic immune changes in ASD Peripheral changes. In addition to immune dysregulation in families, especially in mothers, there is ample evidence of ongoing immune dysfunction in the peripheral immune system and the brain of individuals with ASD 103 . Similar to their relatives, individuals with ASD have an increased incidence of autoimmune disorders, allergies and asthma 66, 104 . A subset of individuals with ASD also have autoantibodies that are reactive to CNS self-proteins, including serotonin receptors 105 , glial fibrillary acidic protein 105 , myelin basic protein [106] [107] [108] , and unidentified targets in the basal ganglia, prefrontal cortex, cingulate gyrus and cerebellum 105, 106, [108] [109] [110] [111] [112] [113] . Because unaffected siblings of people with ASD have similar autoantibody profiles 108, 114 , brain-directed autoantibodies may not be generally predictive of ASD and may instead represent secondary autoimmune processes or evidence of a previous CNS injury. Nevertheless, a recent study found an association between specific autoantibodies that recognize cerebellar targets of 45 kDa and 65 kDa and ASD diagnosis, impaired behavioural scores and lower cognitive and adaptive function 115 . Interestingly, the maternally derived anti-brain autoantibodies discussed above have a much higher degree of association with ASD diagnosis and specific pathophysiology than patients' own autoantibodies. This discrepancy may represent a critical difference in the timing of exposure, with insults during gestation having greater pathogenic impact than later-stage insults owing to the limited potential for exposure after the BBB is formed and brain architecture is more developed.
In addition to the presence of autoantibodies, many reports have identified changes in cytokine levels in the blood of individuals with ASD who are over 2 years of age. These changes include increases in the levels of IL-1β, IL-6, IL-8, IL-12p40 (also known as IL-12β) and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are generally considered to be pro-inflammatory cytokines, and decreases in the levels of IL-10 and transforming growth factor-β (TGFβ), which are generally considered to be anti-inflammatory cytokines [116] [117] [118] [119] [120] [121] . The lower levels of TGFβ in these children with ASD are associated with less adaptive behaviours and worse behavioural symptoms 119 . Increases in the levels of IL-1β, IL-6, IL-8 and IL-12p40 are specifically associated with a regressive form of ASD and more impaired stereotypical behaviours, and increases in the levels of the chemokines C-C motif chemokine 2 (CCL2; also known as MCP1), CCL5 and eotaxin are associated with higher aberrant behaviour scores and more impaired development 121 . These changes in peripheral cytokine levels may be developmentally regulated, as measurements at earlier ages differ in both the cytokines altered and the direction of their change in ASD. For example, the levels of several cytokines were decreased (GM-CSF, interferon-γ (IFNγ), IL-2, IL-4 and IL-6) in neonatal blood samples taken from individuals who were later diagnosed with ASD in a large recent longitudinal study using the Danish Newborn Screening Biobank 122 . Importantly, similar to the situation for peripheral autoantibodies and ASD, peripheral cytokine profiles in individuals with ASD and their unaffected siblings are similar 123 , suggesting that these changes alone may not be sufficient to cause ASD.
In addition to altered cytokine profiles, evidence exists for impaired immune cell function and responsiveness following immune challenge in ASD. Natural killer cells from individuals with ASD are defective in their normal function of lysing infected cells when challenged 124, 125 . Monocytes isolated from individuals with ASD also exhibit impaired responses to challenge: they secrete excess pro-inflammatory cytokines following challenge with ligands for Toll-like receptor 4 (TLR4; a receptor that is responsive to bacterial pathogens) but show reduced production of these same cytokines when challenged with ligands for TLR9 (a receptor that is responsive to viral pathogens) 125, 126 . Similarly, circulating levels of CD4 + T cell populations are low, biased towards an anti-inflammatory (T helper 2 (T H 2)) profile and exhibit a dysfunctional response to stimulation in individuals with ASD [127] [128] [129] [130] [131] . Studies trying to associate particular cellular immunophenotypes with symptom severity have produced seemingly contradictory results. For example, T cell skewing to a T H 2 phenotype (which is considered to be anti-inflammatory and is found in a subset of the ASD population) has been associated with better cognitive and adaptive behaviour 127, 132 , but in another study increased levels of the classical T H 2 cytokine IL-4 have been associated with greater impairments in non-verbal communication 120 . Despite these ambiguities, sufficient evidence indicates that general abnormalities in peripheral immunity are a common feature in the population of individuals with ASD.
Studies in mice have provided further support for an association between peripheral immune changes and ASD. The offspring of MIA mice exhibit peripheral immune abnormalities. For example, T cells from adult MIA offspring secrete excess pro-inflammatory cytokines when challenged and show a bias towards Box 2 | Considerations for interpreting results from animal models of ASD Despite the excitement surrounding the relevance of the maternal immune activation (MIA) model to autism spectrum disorder (ASD), there are several caveats that must be considered in interpreting results from this model. First, it is important to note that MIA models a single environmental risk factor amid a sea of implicated genetic and environmental susceptibilities for ASD and therefore should not be expected to capture all of the diverse phenotypes across the autism spectrum. Second, MIA is a shared environmental risk factor for a wide range of neuropsychiatric and degenerative disorders that manifest at distinct time points during life. Therefore, MIA models also should not be expected to express pathophysiology exclusive to ASD. It is important to note that these caveats are not exclusive to the MIA models, but rather are also applicable to monogenetic animal models of ASD. Similar to some of the MIA models, most of the genetic ASD models fail to recapitulate the full pathophysiology observed in individuals with ASD. In some instances, genetic models either show no overt pathology or demonstrate behaviours that are opposite to those characterizing ASD 257, 258 . Moreover, many of the genes that were initially thought to be exclusively linked to ASD have turned out to be shared risk factors for other neuropsychiatric disorders, particularly schizophrenia. Rather than undermining their relevance to ASD, the caveats to preclinical ASD animal models could be embraced and used experimentally to test hypotheses and develop molecular models for the cause of different forms of ASD and other disorders. These models provide a reductive platform from which we can build more complex models, such as pairing MIA with specific genetic backgrounds or later-life immune insults. For example, pairing a low dose of polyinosinic:polycytidylic acid at gestation day 9 with chronic mild stress at adolescence unmasked schizophrenia-like behaviours and biomarkers in mice 259 . In the future, similar pairings of MIA with other ASD risk factors may parse the phenotypic heterogeneity of ASD into subtypes of this condition, as well as other disorders, reflecting specific combinations of genetic and environmental insults during particular developmental periods of susceptibility.
Gut microbiota
A diverse set of microorganisms that inhabit the gut and shape host immune function. 101, 133, 134 . In addition, myeloid cells from these animals are increased in number and produce higher levels of IL-12p40 and CCL3, which is consistent with a pro-inflammatory immune profile 133, 135 . Collectively, these findings suggest that MIA induces an irregular immune phenotype that persists into adulthood in rodents, as in ASD, but is distinct in nature from the T cell response profile in ASD. However, comparing results from animal studies using a single model (MIA) with ASD in humans resulting from a wide range of aetiologies may be misleading. Moreover, cross-species comparisons from the current literature are not informative because of the often limited number of cytokines assayed in human samples, the wide range of ages, co-morbidities and therapies within the patient population, and the challenge of comparing postnatal ages between rodents and humans. Nevertheless, these studies do clearly show that an environmental risk factor for ASD causes long-lasting immune dysregulation that is associated with ASD-like phenotypes in rodents. Importantly, future studies with larger numbers of individuals with ASD are needed to determine whether there is a consistent peripheral cytokine signature that is diagnostic for ASD or even negatively associated with ASD expression in unaffected siblings.
T H 1 and T H 17 phenotypes
Immune changes in the CNS.
It is often assumed that changes in cytokine levels in the blood from individuals with ASD reflect changes in cytokine levels in the brain. The findings of some studies are consistent with this idea, reporting increases in GM-CSF, IL-6, IL-8, TNF and IFNγ levels in the frontal cortex, and increases in IL-6, TGFβ and CCL2 levels in the anterior cingulate gyrus and cerebellum 116, 136, 137 . As further evidence of potential neuroinflammation, microglia in the dorsolateral prefrontal cortex exhibit increased MHCII expression (a marker of activation), an activated morphology (amoeboid shape) and increased density 138, 139 . However, other results contradict these findings: some studies have shown decreases or no change in sensitive markers of CNS immune activation -including quinolinic acid, neopterin and biopterin -in the cerebrospinal fluid of individuals with ASD [140] [141] [142] . Similarly, increases in the levels of soluble TNF receptors that blunt the inflammatory response are present in the cerebrospinal fluid and serum from individuals with ASD 142 . Future studies defining the roles for ASD-associated changes in cytokines as mediators of neuroinflammation, as dynamic adaptive responses to peripheral changes or simply as growth factors or neuromodulators will be crucial to explain these contradictory findings.
In mouse models of MIA, offspring with ASD-like behaviours and neuropathology also exhibit long-lasting changes in cytokine levels in the brain. The levels of a broad range of cytokines are increased in the fetal brain hours after poly(I:C) injection in pregnant mice 143, 144 , and many of these cytokines remain chronically altered in the brains of offspring throughout postnatal development and into adulthood 145 . Although cytokine levels are generally increased at birth and in the adult brain, levels of many cytokines are decreased in frontal cortical regions during peak periods of synaptogenesis and plasticity 145 . These changes do not correlate with changes in serum cytokine levels and are not accompanied by changes in BBB permeability or immune cell infiltration into the brain parenchyma. Thus, these results do not fit the classical definition of neural inflammation and suggest caution in interpreting changes in cytokines levels at one time point as indicative of an inflammatory process 146 
. Understanding how a discrete event of immune activation during pregnancy causes ongoing and dynamic dysregulation of immune molecules in the brains of offspring is one of the most important areas for future research in this field.
In addition to altered cytokine levels, the brains of individuals with ASD also show changes in the expression of genes encoding proteins that were initially discovered in the immune system. A weighted gene co-expression network analysis comparing the expression of more than 30,000 genes in post-mortem autistic and control brains revealed two distinct networks -each comprising more than 400 genes -that are disrupted in the brains of individuals with ASD 30 . One of the networks of genes is associated with synaptic function and is downregulated in ASD, whereas the other module contains immune-related genes and is upregulated in ASD. Taken together, these results indicate ongoing dysregulation of the immune system and altered expression of immune molecules in the CNS in ASD and in mouse models of MIA. How these changes relate to the pathophysiology observed in these individuals and animal models remains unclear. As the immune system is primarily involved in tissue repair and homeostatic processes, these alterations could represent compensatory responses to dysfunctional network activity and cellular stress. Studies addressing the temporal dynamics of these central alterations with age and whether they are linked to the ongoing and dynamic immune changes in the periphery are important areas for future research.
A role for the microbiota? Adding to the complexity of the neural-immune axis is the recent focus on the gut as an important nexus for nervous-immune-endocrine system interactions. The initial colonization of the gut is dominated by maternal microbiota during birth, and this formative colonization assists in priming the developing immune system and directs immune homeostasis [147] [148] [149] . Children with ASD have excessive levels of Clostridium spp. and Desulfovibrio spp. in their gut microbiome [150] [151] [152] , and this imbalance could influence peripheral immune responses and potentially contribute to the observed abnormalities in immune cell composition and function in these individuals. In fact, recent studies suggest that gut microbiota may act as a 'tuning fork' for the immune system. In particular, the composition of gut microbiota strongly influences the T cell repertoire, which is defined as the various subtypes -each with their own effector properties -and myriad T cell receptor clones within these subtypes 153, 154 . Certain microbiota signatures in the gut inhibit the differentiation of brain-supportive T cell populations, and administration of Bacteroides fragilis restores the proper balance of T cell populations in mice 155 .
The idea that therapies directed at altering the gut microbiota may regulate immune function and rescue ASD-related phenotypes has received support from animal models of ASD. Offspring from the poly(I:C) mouse model of MIA exhibit gastrointestinal changes that are also found in some humans with ASD 156, 157 , including increased intestinal permeability and abnormal intestinal cytokine profiles 158 . These MIA offspring also have abnormal microbiota signatures, most significantly in increased levels of Clostridium spp., paralleling findings in humans with ASD 151, 159 . Remarkably, oral treatment with B. fragilis restores intestinal permeability and serum cytokine levels, rectifies microbiota imbalances, ameliorates stereotypical and anxiety-like behaviour, improves sensorimotor gating, and increases the number and duration of ultrasonic vocalizations in these mice 158 . Interestingly, B. fragilis has no effect on the deficits in sociability in these offspring. Future studies will determine whether social behaviours are resistant to probiotic therapy, whether B. fragilis also reduces the underlying neuropathology and whether it does so through normalizing immune dysregulation in offspring.
Potential mechanisms
As our understanding and appreciation of neuralimmune crosstalk continue to grow, there is an increasing focus on determining how immune dysregulation might alter brain connectivity and function to contribute to ASD-like phenotypes. In the past 10 years, immune molecules on neurons or glia in the brain have been demonstrated to regulate every stage of brain development and function 160, 161 . The body repurposes immune cells, immune molecules and their receptors for widely divergent tasks in both region-specific and developmental-stage-specific manners. Alterations in the expression of these immune molecules in the brain, by genetic mutations or as a result of environmental risk factors, can lead to transient and/or lasting changes in brain development and function.
Cytokines. Findings from both epidemiological studies and animal models indicate that cytokine imbalances can disturb fetal development and/or chronically impair brain function 162 . Cytokines and their receptors are expressed by neurons and glia throughout development and regulate a diverse array of physiological processes in brain development, plasticity and function 160 . For example, IL-1β and its receptors have important roles in a wide range of processes, including neurogenesis and synapse formation and plasticity, from early prenatal CNS development to postnatal development and adulthood [163] [164] [165] [166] [167] [168] [169] . Moreover, a mouse model mimicking the ASD-associated null mutation in IL1RAPL1 exhibits reduced cortical synapse density, an enhanced ratio of excitation to inhibition in the amygdala and deficits in associative memory 169, 170 . These findings are similar to those found in Mecp2-null mice, a model of Rett syndrome 170, 171 . IL-1β functions within a tight homeostatic range; deviations above or below physiological levels lead to impairments in long-term potentiation and synaptic plasticity -two key molecular processes thought to underlie learning and memory 172 . Several other pro-inflammatory cytokines, including TNF, have similar diverse roles in early brain development and postnatal synaptic plasticity 173, 174 . IFNγ also negatively regulates homeostatic processes during experience-dependent plasticity in the visual system 175 . Collectively, these findings suggest that increases or decreases in cytokine levels owing to genetic mutations or downstream of MIA could have deleterious effects on brain development and function independent of any role in inflammation (BOX 3; FIG. 2) .
Box 3 | Detecting neuroinflammation
Inflammation in the body is a protective, organized and adaptive response to invading pathogens 260 that is rigorously defined by four hallmarks: increases in pro-inflammatory cytokine levels, activation of macrophages, recruitment of leukocytes to sites of inflammation and local tissue damage. Inflammation begins with an abrupt rise in the levels of pro-inflammatory cytokines, followed by a gradual rise in the levels of anti-inflammatory cytokines, which limits damage to secondary tissues. Classically, neuroinflammation occurs when the nervous system is exposed to infection or trauma that is accompanied by breaches in the blood-brain barrier (BBB). Under these conditions, microglia and astrocytes adopt a reactive phenotype (gliosis), and proliferate and perpetuate cellular and molecular responses that are aimed at removing infected or damaged tissue. Prolonged gliosis can recruit peripheral leukocytes, amplify the initial tissue damage and thereby cause neurodegeneration in the surrounding healthy tissue.
In the past 10 years, since our ability to measure cytokine levels and microglial morphology in the brain has become routine, the definition of neuroinflammation has grown increasingly murky to the point that the presence of any single hallmark of classical inflammation is now sufficient to define a disease as being 'inflammatory'. Reports of increased levels of pro-inflammatory cytokines in the post-mortem brains of individuals with autism spectrum disorder (ASD), in particular, have led to the hypothesis that chronic neuroinflammation plays a part in ASD pathogenesis. However, numerous studies cited as supporting this hypothesis have assessed only a handful of pro-inflammatory cytokines (typically interleukin-1β (IL-1β), IL-6, tumour necrosis factor (TNF) and interferon-γ (IFNγ)) without reporting any other hallmark of neuroinflammation 120, 136, 142 . Individual cytokines function as part of a larger homeostatic network of both pro-and anti-inflammatory, as well as regulatory, cytokines in which each factor can influence the synthesis and action of the other factors 261 . Thus, the impact of these cytokine networks on immune cells and tissues cannot be inferred from examining the levels of individual cytokines 262 . Determining whether inflammatory conditions predominate requires assessing (at the very least) the levels of a wide range of cytokines as well as the accompanying expected cellular signs of inflammation, such as microglial activation. However, despite the increasing numbers of studies measuring microglial activation, this classification remains subjective and represents a range of morphologies and states that change with developmental age and are only beginning to be understood.
Defining neurological and psychiatric diseases as inflammatory requires even more rigorous assessment within the brain because immune molecules and cells in the CNS are involved in physiological processes that can be mistaken for pathogenesis 263, 264 . Currently, there is no consensus in the ASD field as to which criteria must be met to satisfy the label 'neuroinflammation', despite the widespread assumption that any inflammatory process is detrimental and leads to degeneration. Given the abundance of immune signalling that occurs under physiological conditions in the developing and mature brain, some of which is described in this Review, choosing a definitive set of criteria that constitutes a pathological state will prove to be challenging 265 . Nevertheless, it is particularly important in the case of ASD to define those immune mediators that serve adaptive roles and those that are pathological to better understand the mechanisms underlying this disorder and to tap into the exciting potential of targeting those functions for the future development of new neuroimmune therapies to treat ASD. Nature Reviews | Neuroscience What mechanisms downstream from cytokines affect brain development? In the periphery, numerous cytokines signal through the Janus kinase-signal transducer and activation of transcription (JAK-STAT) pathway, which comprises three mammalian JAK and seven STAT proteins 176 . Receptor binding activates the kinase function of JAK, which recruits and phosphorylates STAT. Upon STAT dimerization, the complex translocates to the nucleus, where it regulates the transcription of genes involved in cell growth, differentiation and function, and immune genes including those encoding MHCI molecules. Although it is unknown whether the JAK-STAT pathway works in similar ways in the brain, recent reports suggest that JAK-STAT signalling is important for normal brain functions and that cytokines regulate this signalling in neurons. For example, STAT1 is upregulated in the visual cortex following long-term monocular deprivation, where it regulates AMPA receptor surface expression and synaptic function 175, 177 . Moreover, IFNγ enhances STAT1 expression, which reduces visual cortical plasticity 175 . STAT1 is also implicated in spatial learning 178 , and STAT1 and STAT3 have roles in hippocampal plasticity 179, 180 . Although JAK-STAT signalling in the brain has just begun to be explored, it may represent an important therapeutic target for pathogenic cytokine-mediated alterations in brain development and function, such as those described above for ASD.
MET. In addition to regulating immunity, MET has essential roles in the brain throughout development. MET is expressed throughout the neocortex, hippocampus 181 , cerebellum 182 and brainstem 183 , where it is enriched in excitatory pre-and postsynaptic compartments 184 . MET signalling induced by HGF increases the levels and clustering of synaptic proteins 185, 186 , increases the number of dendritic spines 187 , modulates hippocampal synaptic function 186, 188 and enhances hippocampal long-term potentiation 189 . Moreover, decreases in MET expression confer local hyperconnectivity, which is a putative hallmark of ASD pathophysiology 190 . Consistent with these results, reduced MET expression, as seen in ASD, alters key neurodevelopmental processes and is associated with structural and functional alterations in ASD 26 . Further investigation is needed to determine whether targeting downstream MET signalling modulates circuit activity and ameliorates the impairments in socio-communicative function associated with decreased MET expression 31 .
MHC class I molecules. MHCI molecules have been implicated in ASD through genetic associations (described above) and as downstream effectors of MIA 191 . MHCI molecules are found on all nucleated cells in the body, where they mediate the adaptive and innate immune responses. They are also present in neurons and glia throughout the CNS of many mammalian species 192, 193 . In cortical pyramidal neurons, MHCI is present both pre-and postsynaptically at glutamatergic synapses, where its surface expression is tightly modulated by activity, therefore allowing it to regulate synaptic plasticity 192, [194] [195] [196] [197] [198] [199] [200] . During CNS development, MHCI controls axonal and dendritic outgrowth, negatively regulates the initial establishment of cortical connections and promotes synapse elimination during activity-dependent refinement of connections in the developing visual system 191, 193 . Interestingly, poly(I:C)-induced MIA in mice causes a dramatic increase in the expression of MHCI molecules on cortical neurons from newborn offspring. Dissociated neurons from MIA offspring also exhibit a profound deficit in their ability to form glutamatergic synapses. Remarkably, normalizing the levels of MHCI in cultured MIA neurons prevents the MIA-induced decrease in synapse density 191 . Thus, changes in MHCI signalling may be a common mechanism through which mutations in MHC genes and exposure to maternal infection could alter the establishment of connectivity in the developing brains of offspring. Whether changes in MHCI levels act downstream of mutations in other immune or non-immune ASD-linked genes, use convergent ASD-linked signalling hubs at the glutamatergic synapse or contribute to ASDrelated behaviours are active areas of investigation.
MEF2 transcription factors.
Although myocyte-specific enhancer factor 2 (MEF2) transcription factors are not classical immune molecules, they seem to mediate the effects of immune dysregulation on synaptic connectivity. These transcription factors are also associated with ASD risk through genetic mutations and act as central molecular hubs downstream of several other ASD risk factors. MEF2 transcription factors regulate gene expression in an activity-dependent manner, affecting the expression of many proteins that regulate synaptic plasticity and function during neural development 201, 202 . Interestingly, MEF2C haploinsufficiency syndrome is a recently discovered neurodevelopmental disorder that is characterized by autism-like behaviours, intellectual disability, high rates of epilepsy and abnormal movements 203 . MEF2 negatively regulates the establishment of hippocampal connections 202 and mediates the effects of MHCI on cortical connectivity in normal brain development and the MIA-induced deficit in synapse formation in newborn neurons 191 . In the genome-wide transcriptional profiling study of ASD 30 that was mentioned previously, the MEF2 splicing factor ataxin 2-binding protein 1 (A2BP1; also known as RBFOX1) -previously implicated in ASD 204, 205 -was identified as a central hub within the network of downregulated genes associated with synaptic function. Moreover, in an integrative functional genomic analysis of ASD-associated genes, two co-expressed networks Figure 2 | Immune molecules at glutamatergic synapses. At the 'quad-partite' synapse 218 , pre-and postsynaptic neurons, astrocytes and microglia communicate using immune mediators, many of which are altered in individuals with autism spectrum disorder (ASD). Each panel represents molecular pathways that are used by immune molecules at the synapse to regulate synapse formation and/or plasticity. a | Major histocompatibility complex class I (MHCI) molecules are located at synapses, where they act through calcineurin to activate myocyte-specific enhancer factor 2 (MEF2) transcription factors to negatively regulate synapse strength and density. MHCI-dependent activation of MEF2 requires calcium influx through NMDA receptors (NMDARs) and voltage-gated calcium channels (VGCCs), although the molecules linking increases in MHCI expression and increases in NMDAR and VGCC conductance remain unknown (denoted by the question mark). MEF2 can act in concert with fragile X mental retardation protein 1 (FMRP) to stimulate the ubiquitylation of postsynaptic density protein 95 (PSD95) and increased association with protocadherin 10 (PCDH10), which then chaperones PSD95 to proteasomes for degradation. b | In general, cytokines released by astrocytes, microglia and/or neurons bind to their specific receptors and activate Janus kinase-signal transducer and activation of transcription (JAK-STAT) signalling at the synapse and alters transcription, leading to the negative regulation of AMPA receptor (AMPAR) expression, either through inhibiting new insertion or increasing internalization. Growth factors, especially hepatocyte growth factor (HGF), are also thought to be secreted from glial cells into the synaptic cleft, where they bind to and activate MET, which negatively regulates AMPAR expression, possibly through STAT-mediated transcription. Chemokines are also presented by neurons and bind to receptors on glial cells, depicted here for the interaction between CX3C chemokine receptor 1 (CX3CR1) on microglia and its ligand, CX3CL1, secreted by neurons or expressed in a tethered form on the neuronal cell surface. CX3CR1-CX3CL1 signalling is required for the migration of sufficient numbers of microglia into the brain in early development and, at older ages, for synaptic plasticity under physiological conditions. c | Interleukin-1β (IL-1β) exerts distinct effects at the synapse. Binding of IL-1β to IL-1 receptor type 1 (IL-1R1) recruits the IL-1 receptor accessory protein (IL-1RAcP), which increases NMDAR signalling. Unbound IL-1RAcP acts as a trans-synaptic adhesion molecule through its interactions with presynaptic protein tyrosine phosphatase-σ (PTPσ), PTPδ and leukocyte common antigen related (LAR). IL-1R accessory protein-like receptor 1 (IL-1RAPL1) also acts as a synaptic organizer by binding to presynaptic PTPδ. These trans-synaptic interactions exert multiple effects on synapse formation and plasticity, as described in the main text. d | Astrocyte-secreted transforming growth factor-β (TGFβ) binds to neuronal TGFβ receptor 2 (TGFβR2) (placed here presynaptically owing to findings at the neuromuscular junction), which induces neuronal secretion of the complement protein C1q. C1q initiates the complement cascade, leading to cleavage of C3 into C3b, which binds to synaptic surfaces. Microglial expressed complement receptor 3 (CR3) recognizes tagged synapses and initiates synaptic pruning at a subset of synapses. CX3CR1-CX3CL1 is also required for microglia-mediated synaptic pruning in early development, and spine elimination and formation in mature circuits. Although currently unknown, local neuron-microglia signalling through CX3CR1-CX3CL1 may serve as an instructive signal for complement-mediated synaptic pruning.
◀ Phagocytosis
The engulfment of extracellular pathogens or cellular debris by certain immune cells, including microglia.
upregulated during early fetal development and during late fetal-early postnatal development showed binding site enrichment for two isoforms of MEF2 (MEF2A and MEF2C) 206 that are predicted to drive the transcriptional co-regulation of both processes. In addition, MEF2 interacts with fragile X mental retardation protein 1 (FMRP; encoded by FMR1 in humans) to regulate glutamatergic synaptic function 207 , and this interaction controls the expression of protocadherin 10 (Pcdh10), which is another ASD-linked gene and is necessary for MEF2-mediated activity-dependent synapse elimination 208 . Together, these findings suggest that ASD that is associated with immune dysregulation during gestation, as well as idiopathic and syndromic forms of ASD, may converge on a molecular pathway with MEF2 as a hub 209 . Identifying new therapeutic targets within the signalling cascades upstream and downstream of MEF2 should be a priority for ASD research owing to their potential efficacy in treating a wide range of disorders on the autism spectrum.
Microglia and complement. Microglia and complement may -similar to cytokines, MHCI molecules and MEF2 -also mediate the effects of both environmental and genetic ASD risk factors. Activated microglia are present in increased numbers and with an altered distribution in post-mortem brain tissue, especially the prefrontal cortex, in a subset of ASD cases 116, 138, 210, 211 . Although microglia are best known for their role in clearing debris following injury, they have recently been shown to have important roles in the normal brain 212 . During development, microglia phagocytose debris from naturally occurring cell death, secrete trophic factors such as insulin-like growth factor 1 (IGF1) and TGFβ, regulate neurogenesis through phagocytosis of neural precursor cells and participate in activity-dependent elimination of synaptic connections [213] [214] [215] . Deficits in microglia, such as those seen in the CX3C chemokine receptor 1 (Cx3cr1)-knockout mice, lead to increased densities of immature synapses in the cerebral cortex, deficits in functional connectivity across brain regions and ASD-like behaviours 216, 217 .
Components of the complement cascade may mediate some of these microglial functions. In the peripheral immune system, the complement pathway mediates clearance of cellular debris and increases the degree of antibody binding to circulating bacteria and infected cells, thereby enhancing their destruction. Intriguingly, the complement C4 gene lies within the MHC region, and deficiencies in C4 are associated with ASD 51, 129, 218 . Complement deficiency is also strongly linked to autoimmune disorders, especially SLE 219 . In the brain, the complement protein C1q is secreted by neurons 220 . Although many of the details of the complement cascade in the brain are unknown, C1q typically forms complexes with other C1 proteins to activate the C3 convertase, which cleaves C3 into opsonizing fragments in the periphery 221 . One of these fragments, C3b, is thought to tag weak synapses in the CNS. These tagged synapses are subsequently pruned through phagocytosis by microglia expressing complement receptor 3 (CR3) 222 . Thus, early immune insults have the potential to diminish or enhance microglia-mediated synaptic pruning.
Astrocyte-dependent secretion of TGFβ regulates C1q expression and deposition in the lateral geniculate nucleus 223 . Because TGFβ levels are increased in the cerebrospinal fluid and in post-mortem brain tissue from individuals with ASD 116 , it is possible that these increases in TGFβ levels in ASD brains could cause and/or reflect compensatory or pathology-inducing alterations in synaptic pruning. Importantly, microglia, similar to their macrophage relatives in the periphery, can be primed early in development 224 . Depending on the developmental trigger, altered priming can impair or enhance reactions to subsequent immune challenges 225, 226 . Whether, and how, this immune priming contributes to ASD phenotypes remains an important area for future research.
Perspective
A common pathway?
The results reviewed here suggest that many of the diverse immune contributions to ASD -including dysregulated signalling through MET, cytokines, MHCI molecules and microglia-complement -share the downstream effect of regulating synapse formation and elimination, thereby controlling synaptic function and plasticity in the developing and mature brain. Although research into the molecular mechanisms used by these immune ASD risk factors is in its infancy, one common signalling hub -MEF2 -has already been identified (FIG. 3) . Importantly, this hub also mediates the effects of mutations in MEF2 and FMR1 in contributing to ASD-related phenotypes.
In addition to converging on MEF2 signalling, it is likely that many immune risk factors will converge on the most common intracellular signalling hub for ASDrisk genes -mammalian target of rapamycin (mTOR). Numerous studies of monogenic forms of ASD have implicated the mTOR pathway in ASD 227 . mTOR is a serine/threonine protein kinase that controls many aspects of neural development as well as the function and plasticity of the mature brain 228, 229 . This pathway integrates signals from growth factors and hormones, neurotransmitters, cytokines and stress mediators, and involves crosstalk between two intracellular signalling cascades -RAS-ERK and PI3K-AKT -that are essential for immune and neuronal function. In the immune system, mTOR integrates signals from the immune microenvironment to direct immune cell metabolism, differentiation and function, and is important for mounting an adaptive immune response 230 . Alterations in mTOR signalling seem to underlie several common monogenic forms of ASD, including fragile X syndrome, tuberous sclerosis, Rett syndrome, PTEN macrocephaly and neuro fibromatosis type 1, and syndromes with autistic-like features, such as MEF2C haploinsufficiency and 9q34.3 deletion syndrome. Interestingly, IGF1, which ameliorates some behavioural abnormalities and neuropathologies of Rett syndrome and 22q13 deletion syndrome and is secreted by microglia, activates mTOR 231 . Although most of the immune risk factors for ASD discussed above have not yet been directly studied for their effects on mTOR, there is some evidence to date that is consistent with the hypothesis that immune dysregulation may converge on this central signalling pathway. For example, MET translates extracellular signals into mTOR activation; thus, the ASD-related MET 'C' variant is predicted to lead to hypoactive mTOR signalling 232 . Moreover, many cytokine receptors found at the synapse typically activate mTOR signalling in the periphery, potentially causing phenotypes similar to monogenic forms of ASD. Although it is unknown whether mTOR is activated in response to cytokines in the brain, the signalling components for mTOR are present in neurons and are activated by a growing list of growth factors, guidance molecules and neurotransmitters 228 . mTOR is therefore a focal point to integrate immune signalling in the brain, changes in cytokine levels due to MIA, postnatal environmental insults or mutations in immune genes, and ongoing immune dysregulation throughout life. Determining whether, and how, the immune contributions discussed in this Review converge on this common mTOR pathway will be crucial for determining how pervasive mTOR signalling is across the diverse forms of ASD and for the development of new therapeutics that target mTOR in the future.
Therapeutics. One of the most exciting implications of the discovery that immune dysregulation may contribute to ASD is the possibility that agents targeting immune function could alleviate some of the symptoms associated with this spectrum of disorders. One of the most effective, albeit drastic, therapeutic approaches for restoring immune function is bone marrow transplantation. Remarkably, transplantation to reconstitute the brain with wild-type microglia reverses somatic phenotypes, neuropathological changes and behavioural abnormalities in two mouse models of ASDthe Mecp2 −/y model of Rett syndrome 233 and the MIA model 133 . Full immune system reconstitution from control animals also rescues peripheral immune abnormalities in MIA offspring, including deficits in regulatory T cells and a disproportionate increase in CD4 + memory T cells with an inflammatory profile previously implicated in learning and memory deficits 132, 133 
. On the basis of these animal studies, clinical trials using strategies to reconstitute immune cells in individuals with ASD have been initiated 234, 235 . Another class of potential therapies targeting immune function is anti-inflammatory or immunosuppressive agents. To date, therapies in this category have focused on decreasing the assumed ongoing inflammation in the periphery and brain of individuals with ASD. Consistent with this idea, minocycline, a broad-spectrum antibiotic that has immunosuppressive properties, corrects synaptic abnormalities, heightened anxiety and social deficits in Fmr1-knockout mice 236, 237 . In a randomized doubleblind, placebo-controlled trial in children and adolescents with fragile X syndrome, 3 months of minocycline treatment improved anxiety and mood-related behaviours 238 . Although antibiotic treatment may also improve symptoms in idiopathic forms of ASD [239] [240] [241] , ASD with regressive features may be resistant to minocycline therapy 242 . The exact immunomodulatory mechanisms of minocycline are unknown; however, it may exert its effects through a combination of suppressing cytokine signalling, enhancing neurotrophic factor secretion and suppressing mTOR signalling 243 . Minocycline could relieve ASD-related phenotypes directly through altering neural function or indirectly through ameliorating ongoing immune dysfunction or through regulating the intestinal microbiota 241 . Figure 3 | Synaptic immune signalling converges on mTOR. Immune and neuronal receptor signalling activates various intracellular molecular pathways that feed into the mammalian target of rapamycin (mTOR) pathway and activate myocyte-specific enhancer factor 2 (MEF2)-dependent transcriptional regulation. These central signalling pathways may become dysregulated through genetic mutations or environmental exposures that are associated with autism spectrum disorder (ASD) and thereby alter neural development and function. mTOR activity regulates numerous processes, including protein synthesis, mitochondrial function, lipid synthesis, cell growth and proliferation, synaptic plasticity, neurogenesis, neuronal cell death, ion channel expression and cytoskeletal dynamics. Importantly, mTOR complex 1 (mTORC1) regulates the synthesis of glutamatergic receptors and protein products, including SH3 and multiple ankyrin repeat domains protein (SHANK), synapse-associated protein 90/ postsynaptic density protein 95 (SAP90/PSD95)-associated protein (SAPAP), neuroligins, and AMPA and NMDA receptor subunits, many of which are genetically associated with ASD. Mutations in the genes that cause most of the syndromic forms of ASD -fragile X mental retardation 1 (FMR1), neurofibromin 1 (NF1), phosphatase and tensin homologue (PTEN), tuberous sclerosis 1 (TCS1) and TCS2 -disrupt components of the mTOR signalling pathway. MEF2 is also implicated in ASD. MEF2C haploinsufficiency syndrome is characterized by ASD-like behaviours, perhaps through the function of MEF2 in regulating transcription during synapse formation and elimination. It is also likely that MEF2 regulates the expression of cytokine receptors in a positive or negative feedback loop, as the promoters of some cytokine receptors (such as interleukin-1 receptor accessory protein-like 1 (IL1RAPL1)) contain a MEF2-binding motif. MEF2 is also a target of the splicing regulator ataxin 2-binding protein 1 (A2BP1) -the central gene in a synaptic module identified in a transcriptome analysis of brain tissue from individuals with ASD. The protein products of genes that have been associated with ASD are shown in dark green. eIF4E, eukaryotic translation initiation factor, 4E; FMRP, fragile X mental retardation protein 1; MHCI, major histocompatibility complex class I; PCDH10, protocadherin 10.
Despite their potential, treatments focused on preventing or ameliorating neuroinflammation in ASD should be considered with caution because the immune dysregulation associated with ASD may not always be pro-inflammatory. As discussed above, mouse models of MIA exhibit decreased levels and function of many types of immune molecules in the brains of offspring during postnatal development, which is the opposite of the widely assumed inflammatory processes present in ASD 145 . Moreover, many of the immune molecules associated with ASD play important parts in brain development, function and plasticity. Thus, altered levels of these immune molecules in ASD may alter brain development through defects in their normal function in addition to, or even rather than, causing inflammation. Finally, it is important to consider the possibility that limited periods of neuroinflammation could be an adaptive response to allow the brain to cope with ASD-related deficits 146 . Studies in humans indicate that fever improves many ASD symptoms, especially deficits in communication and increases in repetitive behaviours [244] [245] [246] . Although these effects have not been directly tested in animal models, several studies suggest that fever temporarily corrects chronic mitochondrial dysfunction -a frequently observed co-morbidity seen in ASD -through alterations in purinergic signalling 247, 248 . The mechanisms underlying these paradoxical effects of fever are important areas of ongoing research, as they may well reveal new therapeutic targets for ASD. If inflammation is indeed adaptive, as implied by these reports, then treating individuals with anti-inflammatory agents could have unintended detrimental consequences. Nevertheless, despite the possible complexity in their roles in ASD, immune molecules provide a new and important set of targets for ASD drug discovery in the future.
Note added in proof
It is important to note that a recent study failed to find any benefit from wild-type microglia transplantation in three rodent models of Rett syndrome 266 , including the model used in the original study 233 . The reason for these divergent findings is unclear, but it will be essential to understand, as it will affect the potential therapeutic value of bone marrow or stem cell transplantation in individuals with Rett syndrome.
